Literature DB >> 9347968

Clearance of Wuchereria bancrofti antigen after treatment with diethylcarbamazine or ivermectin.

M L Eberhard1, A W Hightower, D G Addiss, P J Lammie.   

Abstract

The present study was undertaken to assess the relationship between microfilarial clearance and clearance of circulating filarial antigen from the blood of Wuchereria bancrofti-infected persons following chemotherapy with either diethylcarbamazine or ivermectin. Patients received either 12 weekly doses of 6 mg/kg of diethylcarbamazine (DEC), a single dose of 6 mg/kg of DEC, a single dose of 420 microg/kg of ivermectin, or 20 microg/kg of ivermectin, followed by 6 mg/kg of DEC five days later. Microfilarial clearance was marked in all groups, but was significantly less in the single-dose DEC. In contrast, as monitored by the Og4C3 monoclonal anitbody assay, clearance of circulating filarial antigen was highly variable, not only between groups but within each group. As a result, there were few statistically significant differences in antigen clearance between groups. In no instance did the antigen level fall to zero, even in individuals that remained microfilaria negative during two or three years of follow-up. These results suggest that living adult worms persist in almost all persons treated with DEC and/or ivermectin.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9347968     DOI: 10.4269/ajtmh.1997.57.483

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  7 in total

1.  Elevated levels of plasma angiogenic factors are associated with human lymphatic filarial infections.

Authors:  Sasisekhar Bennuru; Grace Maldarelli; V Kumaraswami; Amy D Klion; Thomas B Nutman
Journal:  Am J Trop Med Hyg       Date:  2010-10       Impact factor: 2.345

2.  Filaria associated clinical manifestations in children in an endemic area and morbidity control by immunomonitoring and optimal DEC therapy: Sevagram experience.

Authors:  B C Harinath; M V Reddy; B Bhunia; Y P Bhandari; V K Mehta; P Chaturvedi; N C Prajapati; R K Gupta
Journal:  Indian J Clin Biochem       Date:  2000-08

3.  Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India.

Authors:  Nilima A Kshirsagar; N J Gogtay; B S Garg; P R Deshmukh; D D Rajgor; V S Kadam; P A Thakur; A Gupta; N S Ingole; J K Lazdins-Helds
Journal:  Parasitol Res       Date:  2017-08-07       Impact factor: 2.289

Review 4.  Drug treatment of tropical parasitic infections: recent achievements and developments.

Authors:  I Stephenson; M Wiselka
Journal:  Drugs       Date:  2000-11       Impact factor: 11.431

5.  An evaluation of Wb123 antibody elisa in individuals treated with ivermectin and albendazole, and implementation challenges in Africa.

Authors:  Dziedzom Komi de Souza; Irene Offei Owusu; Joseph Otchere; Michelle Adimazoya; Kwadwo Frempong; Collins Stephen Ahorlu; Daniel Adjei Boakye; Michael David Wilson
Journal:  Pan Afr Med J       Date:  2017-05-29

6.  First evidence of lymphatic filariasis transmission interruption in Cameroon: Progress towards elimination.

Authors:  Hugues C Nana-Djeunga; Magellan Tchouakui; Guy R Njitchouang; Jules B Tchatchueng-Mbougua; Philippe Nwane; André Domche; Jean Bopda; Stève Mbickmen-Tchana; Julie Akame; Ann Tarini; Emilienne Epée; Benjamin D Biholong; Yaobi Zhang; Jean J Tougoue; Achille Kabore; Flobert Njiokou; Joseph Kamgno
Journal:  PLoS Negl Trop Dis       Date:  2017-06-29

7.  Translating Research into Reality: Elimination of Lymphatic Filariasis from Haiti.

Authors:  Patrick J Lammie; Mark L Eberhard; David G Addiss; Kimberly Y Won; Madsen Beau de Rochars; Abdel N Direny; Marie Denise Milord; Jack Guy Lafontant; Thomas G Streit
Journal:  Am J Trop Med Hyg       Date:  2017-10       Impact factor: 2.345

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.